Gabapentin Capsule
Product Images NDC 71205-295

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

An illustration showing the formula to calculate creatinine clearance (CLCr), involving age, weight, serum creatinine, and a factor for female patients (0.85). This diagram is used for clinical pharmacokinetic assessments.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis shows weeks from baseline to 8, with the study divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 9. Gabapentin shows a decreasing trend in pain score over time, while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph comparing mean pain scores over a 7-week period among three groups: placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis shows weeks from baseline through week 7; the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) groups across two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated for gabapentin groups with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot showing percent difference on the vertical axis and daily dose in mg on the horizontal axis. Data points are grouped by three studies labeled Study a, Study b, and Study c, each with different markers. The plot displays differences for daily gabapentin doses of approximately 600, 900, 1200, and 1800 mg.*

FDA Label Image

71205-295-30 (Gabapentin Fig7)

Gabapentin 300 mg capsules packaging label from Proficient Rx LP. The label specifies a quantity of 30 capsules and indicates that each capsule contains 300 mg of gabapentin USP. Capsules are described as yellow hard gelatin, imprinted with 'D' on the yellow cap and '03' on a yellow body with black edible ink, filled with white to off-white crystalline powder. Manufacturer is Aurobindo Pharma Limited, Hyderabad, India. Storage instructions note 20°-25°C (68°-77°F). Includes NDC 71205-295-30 and multiple lot and expiration placeholders labeled as MASTER.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of gabapentin, showing its cyclohexane ring bonded to an aminomethyl group and a carboxymethyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.